Genentech stock surges as new drugs deliver big revenue

Wall Street was cheering Genentech's high-priced roster of biotech meds, bidding up the biotech giant's stock price after it announced a whopping 73 percent increase in quarterly profits. Operating revenue jumped 35 percent to $1.5 billion for the three months ended June 30. Genentech Chairman and CEO Arthur Levinson told analysts that the company is in an "exciting phase of transformation and growth," with a string of positive clinical trials behind it and a slate of nine FDA applications ahead.

- read this story from the San Francisco Chronicle for more

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.